ReviewFrontiers in neurology
Self-expanding open-cell carotid stent for symptomatic moderate-to-severe vertebral artery origin atherosclerotic stenosis: a single-center retrospective study.
Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Open-cell self-expanding stents have been used for vertebral artery origin (VAO) atherosclerotic stenosis; however, data on their safety and durability remain limited. Methods: We retrospectively screened 96 patients who were evaluated for potential open-cell self-expanding stent treatment of angiographically confirmed VAO stenosis between February 2015 and December 2020. After exclusion of 62 patients (47 with vertebral artery diameter <4.0 mm and 15 with vertebral artery diameter > = 4.0 mm who declined self-expanding stent treatment), the final treated cohort comprised 34 consecutive eligible symptomatic patients who underwent open-cell self-expanding stent implantation. Clinical outcomes were assessed perioperatively and during follow-up. The 30-day safety endpoint included stroke, myocardial infarction, and death. ISR was evaluated among patients who completed imaging follow-up; DSA-confirmed ISR and ISR among all patients with imaging surveillance were both reported. Results: Of 96 screened patients, 34 symptomatic treated patients were included. Three patients entered the symptomatic 50-69% stenosis pathway after insufficient response to medical therapy, and 31 entered the symptomatic > = 70% high-risk anatomic stenosis pathway. Technical success was 100%. VAO stenosis improved from 75.7 +/- 7.9% preprocedure to 8.4 +/- 7.6% immediately after stenting ( Conclusion: In this single-center retrospective series, open-cell self-expanding stent implantation for atherosclerotic VAO stenosis appeared technically feasible and was associated with infrequent periprocedural adverse events. Longer-term durability and optimal patient selection require confirmation in larger prospective studies with standardized imaging follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.